These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

219 related articles for article (PubMed ID: 17165154)

  • 1. Hepatic encephalopathy following transjugular intrahepatic portosystemic shunt (TIPS): management with L-ornithine-L-aspartate and stent reduction.
    Stadlbauer V; Tauss J; Portugaller HR; Stiegler P; Iberer F; Stauber RE
    Metab Brain Dis; 2007 Mar; 22(1):45-50. PubMed ID: 17165154
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Portosystemic hepatic encephalopathy after transjugular intrahepatic portosystemic shunt in patients with cirrhosis: clinical, laboratory, psychometric, and electroencephalographic investigations.
    Nolte W; Wiltfang J; Schindler C; Münke H; Unterberg K; Zumhasch U; Figulla HR; Werner G; Hartmann H; Ramadori G
    Hepatology; 1998 Nov; 28(5):1215-25. PubMed ID: 9794904
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Current diagnosis and management of post-transjugular intrahepatic portosystemic shunt refractory hepatic encephalopathy.
    Pereira K; Carrion AF; Martin P; Vaheesan K; Salsamendi J; Doshi M; Yrizarry JM
    Liver Int; 2015 Dec; 35(12):2487-94. PubMed ID: 26332169
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Type-2 hepatorenal syndrome and refractory ascites: role of transjugular intrahepatic portosystemic stent-shunt in eighteen patients with advanced cirrhosis awaiting orthotopic liver transplantation.
    Testino G; Ferro C; Sumberaz A; Messa P; Morelli N; Guadagni B; Ardizzone G; Valente U
    Hepatogastroenterology; 2003; 50(54):1753-5. PubMed ID: 14696397
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Reversal of transjugular intrahepatic portosystemic shunt (TIPS)-induced hepatic encephalopathy using a strictured self-expanding covered stent.
    Cox MW; Lin PH; Bush RL; Lumsden AB
    Cardiovasc Intervent Radiol; 2003; 26(6):539-42. PubMed ID: 15061178
    [TBL] [Abstract][Full Text] [Related]  

  • 6. [Treatment of refractory hepatic encephalopathy associated with insertion of a transjugular intrahepatic portosystemic shunt through new endovascular techniques: a case report].
    Martínez Moreno B; Bellot P; de España F; Palazón JM; Such J; Pérez-Mateo M
    Gastroenterol Hepatol; 2011; 34(7):468-73. PubMed ID: 21652116
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Endovascular shunt reduction in the management of transjugular portosystemic shunt-induced hepatic encephalopathy: preliminary experience with reduction stents and stent-grafts.
    Maleux G; Verslype C; Heye S; Wilms G; Marchal G; Nevens F
    AJR Am J Roentgenol; 2007 Mar; 188(3):659-64. PubMed ID: 17312051
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effect of L-ornithine-L-aspartate on patients with and without TIPS undergoing glutamine challenge: a double blind, placebo controlled trial.
    Rees CJ; Oppong K; Al Mardini H; Hudson M; Record CO
    Gut; 2000 Oct; 47(4):571-4. PubMed ID: 10986219
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel endovascular adjustable polytetrafluoroethylene-covered stent for the management of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt.
    Weintraub JL; Mobley DG; Weiss ME; Swanson E; Kothary N
    J Vasc Interv Radiol; 2007 Apr; 18(4):563-6. PubMed ID: 17446548
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt insertion: a decade of experience.
    Masson S; Mardini HA; Rose JD; Record CO
    QJM; 2008 Jun; 101(6):493-501. PubMed ID: 18440957
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomised clinical trial: L-ornithine-L-aspartate reduces significantly the increase of venous ammonia concentration after TIPSS.
    Bai M; He C; Yin Z; Niu J; Wang Z; Qi X; Liu L; Yang Z; Guo W; Tie J; Bai W; Xia J; Cai H; Wang J; Wu K; Fan D; Han G
    Aliment Pharmacol Ther; 2014 Jul; 40(1):63-71. PubMed ID: 24832463
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Experiences with novel techniques for reduction of stent flow in transjugular intrahepatic portosystemic shunts.
    Gerbes AL; Waggershauser T; Holl J; Gülberg V; Fischer G; Reiser M
    Z Gastroenterol; 1998 May; 36(5):373-7. PubMed ID: 9654704
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Evaluation of mid- and long-term efficacy of shunt limiting for hepatic myelopathy after transjugular intrahepatic portosystemic shunt.
    Zhao H; Liu F; Yue Z; Wang L; Fan Z
    Clin Res Hepatol Gastroenterol; 2016 Sep; 40(4):440-6. PubMed ID: 26724169
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The presence of spontaneous portosystemic shunts increases the risk of complications after transjugular intrahepatic portosystemic shunt (TIPS) placement.
    Borentain P; Soussan J; Resseguier N; Botta-Fridlund D; Dufour JC; Gérolami R; Vidal V
    Diagn Interv Imaging; 2016 Jun; 97(6):643-50. PubMed ID: 26947721
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Management of transjugular intrahepatic portosystemic shunt (TIPS)-associated refractory hepatic encephalopathy by shunt reduction using the parallel technique: outcomes of a retrospective case series.
    Cookson DT; Zaman Z; Gordon-Smith J; Ireland HM; Hayes PC
    Cardiovasc Intervent Radiol; 2011 Feb; 34(1):92-9. PubMed ID: 21057793
    [TBL] [Abstract][Full Text] [Related]  

  • 16. No effect of albumin infusion on the prevention of hepatic encephalopathy after transjugular intrahepatic portosystemic shunt.
    Riggio O; Nardelli S; Pasquale C; Pentassuglio I; Gioia S; Onori E; Frieri C; Salvatori FM; Merli M
    Metab Brain Dis; 2016 Dec; 31(6):1275-1281. PubMed ID: 26290375
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Primary creation of an externally constrained TIPS: a technique to control reduction of the portosystemic gradient.
    Farsad K; Kolbeck KJ; Keller FS; Barton RE; Kaufman JA
    AJR Am J Roentgenol; 2015 Apr; 204(4):868-71. PubMed ID: 25794080
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Covered vs. uncovered stents for transjugular intrahepatic portosystemic shunt: a randomized controlled trial.
    Perarnau JM; Le Gouge A; Nicolas C; d'Alteroche L; Borentain P; Saliba F; Minello A; Anty R; Chagneau-Derrode C; Bernard PH; Abergel A; Ollivier-Hourmand I; Gournay J; Ayoub J; Gaborit C; Rusch E; Giraudeau B;
    J Hepatol; 2014 May; 60(5):962-8. PubMed ID: 24480619
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Management of refractory hepatic encephalopathy after insertion of TIPS: long-term results of shunt reduction with hourglass-shaped balloon-expandable stent-graft.
    Fanelli F; Salvatori FM; Rabuffi P; Boatta E; Riggio O; Lucatelli P; Passariello R
    AJR Am J Roentgenol; 2009 Dec; 193(6):1696-702. PubMed ID: 19933667
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Hepatic encephalopathy after transjugular intrahepatic portosystemic shunt.
    Riggio O; Nardelli S; Moscucci F; Pasquale C; Ridola L; Merli M
    Clin Liver Dis; 2012 Feb; 16(1):133-46. PubMed ID: 22321469
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.